Ran Nussbaum - 04 Jun 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: KROS
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 16:15:15 UTC
Prior SEC filing: 03 Jun 2024
Next SEC filing: 12 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Keith Regnante, Attorney-in-Fact

Key filing fact

Ran Nussbaum filed Form 4 for Keros Therapeutics, Inc. (KROS) on 06 Jun 2025.

Key facts

This page summarizes Ran Nussbaum's Form 4 filing for Keros Therapeutics, Inc. (KROS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 16:15.

Change

Previous filing in this sequence was filed on 03 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001609805 Primary reporting owner

Nussbaum Ran

Relationship: Director, 10%+ Owner
Address: C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON
Signature: /s/ Keith Regnante, Attorney-in-Fact
Signature date: 06 Jun 2025

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KROS transaction

Common Stock

Award

Transaction value: $0
Shares: +5,250
Change %
Price: $0.000000
Shares after: 5,250
Date: 04 Jun 2025
Ownership: Direct
Footnotes: F1

KROS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,284,612
Date: 04 Jun 2025
Ownership: See footnote
Footnotes: F2

KROS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,121,045
Date: 04 Jun 2025
Ownership: See footnote
Footnotes: F3

KROS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,226,412
Date: 04 Jun 2025
Ownership: See footnote
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +10,500
Change %
Price: $0.000000
Shares after: 10,500
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,500
Exercise price: $14.82
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

Footnote F2

The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

Footnote F3

The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

Footnote F4

The securities are held by China IV. Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

Footnote F5

The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.